MUSK and myasthenia gravis: Mezagitamab (TAK-079), a fully humanized, subcutaneously administered anti-CD38 monoclonal antibody, which has received orphan drug designation for refractory multiple myeloma, was evaluated in a phase II, randomized, double-blind, placebo-controlled trial in patients with AChR- or MuSK-positive MG (ClinicalTrials.gov, NCT04159805) [131].